ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

Company Overview

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Key Stats

• Today's Range: $4.40 to $5.33
• 50-Day Range: $4.54 to $14.63
• 52-Week Range: $4.40 to $4,882.50
• Volume: 124,583 shs
• Average Volume: 704,991 shs
• Market Capitalization: $2.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $700,000.00
• Consensus Rating: Buy

ENDRA Life Sciences Stock Analysis - MarketRank™

ENDRA Life Sciences scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ENDRA Life Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($387.41) to ($311.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ENDRA Life Sciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ENDRA Life Sciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ENDRA Life Sciences has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.63% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 96.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ENDRA Life Sciences does not currently pay a dividend.

Dividend Growth

ENDRA Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.63% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 96.66%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.58

News Sentiment

ENDRA Life Sciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for ENDRA Life Sciences this week, compared to 1 article on an average week.

Search Interest

20 people have searched for NDRA on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, ENDRA Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,041.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.04% of the stock of ENDRA Life Sciences is held by insiders.

Percentage Held by Institutions

Only 1.19% of the stock of ENDRA Life Sciences is held by institutions.

NDRA Stock Analysis - Frequently Asked Questions

How have NDRA shares performed this year?

ENDRA Life Sciences' stock was trading at $185,500.00 at the beginning of the year. Since then, NDRA stock has decreased by 100.0% and is now trading at $4.54.
View the best growth stocks for 2024 here.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($140.00) EPS for the quarter, missing analysts' consensus estimates of ($122.50) by $17.50.

When did ENDRA Life Sciences' stock split?

Shares of ENDRA Life Sciences reverse split on the morning of Tuesday, August 20th 2024. The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did ENDRA Life Sciences IPO?

ENDRA Life Sciences (NDRA) raised $10 million in an IPO on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NDRA
• CUSIP: N/A
• CIK: 1681682
• Web: www.endrainc.com
• Phone: (734) 335-0468
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $700,000.00
• High Stock Price Target: $700,000.00
• Low Stock Price Target: $700,000.00
• Potential Upside/Downside: +15,418,402.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($901.1484)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,060,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -163.18%
• Return on Assets: -128.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.97
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1,170.14 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 490,000
• Free Float: 494,000
• Market Cap: $2.22 million
• Optionable: Not Optionable
• Beta: 0.74